rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TAK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Takeda at Jefferies Global Healthcare Conference: growth plan beyond entyvio
      Nov 17Investing.comJEFTAK
      Takeda launches new narcolepsy pill as DEA completes scheduling
      Nov 12Seeking AlphaTAK
      Takeda launches narcolepsy drug Orzeyful in U.S. market
      Nov 12Investing.comTAK
      Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
      Nov 12ReutersTAK
      Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States

      OSAKA, Japan & CAMBRIDGE, Mass., November 12, 2026--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States

      Nov 12Yahoo FinanceTAK
      Takeda Pharmaceutical Co President Trades $1.16M In Company Stock
      Nov 6BenzingaTAK
      Insider Selling: Teresa Bitetti Unloads $973K Of Takeda Pharmaceutical Co Stock
      Nov 5BenzingaTAK
      Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow

      Takeda Pharmaceutical is reiterated as a hold, with concerns about its ability to replace major drug revenues and current valuation. Read more on TAK stock here.

      Oct 30Seeking AlphaTAK
      What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
      Oct 30Yahoo FinanceTAK
      Takeda bets on blockbuster drug trio to generate $11bn in peak sales

      Stock price rises to highest level in more than 8 years on expectations

      Oct 29NikkeiTAK
      Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
      Oct 29BenzingaTAK
      Earnings call transcript: Takeda tops Q2 2026 estimates, shares rise premarket
      Oct 29Investing.comTAK
      Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript
      Oct 29BenzingaTAK
      Takeda Pharma ADR earnings beat by $1.81, revenue topped estimates
      Oct 29Investing.comTAK
      Takeda Pharmaceutical H1 Core Earnings, Revenue Rise; 2026 Guidance Lifted
      Oct 29Yahoo FinanceTAK
      Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook
      Oct 29Investing.comTAK
      Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
      Oct 29Yahoo FinanceTAK
      Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort

      Japanese drugmaker launches Orzeyful, once thought impossible to develop

      Oct 27NikkeiTAK
      Takeda to seek Japan approval for gastric cancer drug next year
      Oct 25ReutersTAK
      Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
      Oct 23Yahoo FinanceTAK
      Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)
      Oct 20Yahoo FinanceTAK
      H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data
      Oct 16Investing.comHALOTAK
      Takeda Orzeyful: The Best Inventions of 2026

      Find out why Takeda Orzeyful is on TIME's list of 2026's best inventions.

      Oct 15TimeTAK
      Takeda Pharmaceutical Launches Orzeyful in Japan and China
      Oct 15Yahoo FinanceTAK
      Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
      Oct 15Yahoo FinanceTAK
      Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
      Oct 14Yahoo FinanceTAK
      Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline

      Takeda is rated a buy, reflecting recent drug approval, a robust future pipeline, global reach & an investment-grade rating. Click for more on TAK stock.

      Oct 13Seeking AlphaTAK
      Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run

      Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base. For investors watching Takeda stock today, the core issue is how that performance and pipeline story stack up against what the business is actually generating in revenue. Takeda shares are up 120.5% over 5 years, which raises the question of how much of that gain is supported by the company’s sales...

      Oct 1Yahoo FinanceTAK
      Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
      Oct 1Yahoo FinanceTAK
      Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative

      Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in adults with moderate-to-severe plaque psoriasis, with results presented at the 2026 European Academy of Dermatology & Venereology Congress. A particularly important finding is that zasocitinib delivered more than 2.5 times as many patients with complete...

      Oct 1Yahoo FinanceTAK
      Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data

      Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate to severe plaque psoriasis. Taken together with Takeda Pharmaceutical’s oncology pipeline updates and recent leadership change in Spain, the psoriasis data arrives during a period of strong market performance, with the share price up 17.6% year to date and a...

      Sep 30Yahoo FinanceTAK
      Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

      BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

      Sep 29Yahoo FinanceARGXABBVTAK
      Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

      LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of

      Sep 29Yahoo FinanceKROSTAK
      Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
      Sep 29Yahoo FinanceKROSTAK
      Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

      Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

      Sep 25Yahoo FinanceTAK
      Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)
      Sep 23Seeking AlphaALKSTAK
      Roche proposes former Takeda CEO for board seat
      Sep 23ReutersTAK
      Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

      OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (briga

      Sep 22Yahoo FinanceTAK
      Dr. Reddy’s to Roll Out Takeda’s Dengue Jab in India Next Year
      Sep 18BloombergTAK
      Dr Reddy’s to distribute Takeda’s dengue vaccine in India
      Sep 18Investing.comTAK
      Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine
      Sep 18ReutersRDYTAK
      India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

      Sept 18 () - Dr ‌Reddy's ‌Laboratories said ​on Friday it signed ‌a ⁠deal with ⁠Takeda Pharmaceutical ​Company ​for ​the ‌promotion and distribution of the ‌Qdenga ​dengue ​vaccine ​in ‌India. (Reporting by ​Kashish ​Tandon in ​Bengaluru; ‌Editing by ​Sonia ​Cheema).

      Sep 18Yahoo FinanceTAK
      Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

      Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase […]

      Sep 17Yahoo FinanceTAK
      Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
      Sep 17BenzingaTAK
      Takeda at Morgan Stanley global healthcare conference: pipeline turns to launches
      Sep 14Investing.comMSTAK
      Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA
      Sep 14Yahoo FinanceTAK
      Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026

      MALMO, Sweden & WILMINGTON, Del., September 09, 2026--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston.

      Sep 9Yahoo FinanceTAK
      Takeda’s oveporexton shows improvements in narcolepsy study
      Sep 9Investing.comTAK
      A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
      Sep 9The New York TimesTAK
      Bulls Take Control of Takeda Pharmaceuticals: Chart of the Day
      Sep 4Barron'sTAK

      This is the newest page. Registered accounts read further back.